Robert Mitchell
Sintx TechnologiesAbout Robert Mitchell
Robert D. Mitchell, age 63, was appointed to SINT’s Board in April 2025 and is currently a Class II director up for re‑election at the September 4, 2025 annual meeting; if re‑elected his term will run to the 2028 annual meeting . He holds a B.S. from the University of Utah and an M.B.A. from Indiana Wesleyan University, and brings three decades of medical device leadership across public and private companies, including CEO/President roles and global commercial experience .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Endologix, Inc. (public) | President | 2010–2018 | Led commercialization of aortic disorder devices |
| Nellix, Inc. | President & CEO | 2008–2010 | Company acquired by Endologix in Dec 2010 |
| AngioDynamics, Inc. (public) | EVP & COO | 2006–2008 | Senior operating leadership at public medtech |
| Millimed Holdings, Inc. (private, Denmark) | Chairman, President & CEO | 2005–2006 | Led private medtech; international scope |
| Align Technology, Inc. (public) | VP Worldwide Sales | 2004–2005 | Global sales leadership; dental/orthodontic tech |
| Cook Incorporated (private) | Various roles incl. VP & Director, Global Sales & Marketing | 1987–2004 | Spanned diagnostic/interventional, endovascular, critical care |
External Roles
| Organization | Role | Since | Notes |
|---|---|---|---|
| Conavi Medical Corp. (TSX-listed) | Director; Chair, HR & Governance Committee | Mar 1, 2018 | Public (TSX) imaging tech for cardiovascular procedures |
| Life Seal Vascular Inc. (private) | Executive Chairman | Aug 2021 | Endovascular intervention solutions |
| NLP Ventures LLC | General Partner | Jan 2024 | Venture role |
| FF20 Ventures | General Partner | Jan 2022 | Early-stage VC fund |
| RDM Enterprises, LLC | Chairman & Founder | Mar 2018 | Private enterprise |
Interlocks: SINT discloses that, aside from Jay Moyes (Puma Biotechnology, BioCardia), none of its directors serve on boards of SEC-reporting issuers; Mitchell’s Conavi role is TSX-listed (not an SEC registrant) .
Board Governance
- Independence: The Board determined all four non‑employee directors, including Robert Mitchell, are independent under Nasdaq Rule 5605(a)(2) .
- Classification and tenure: Mitchell is a Class II director up for election in 2025; term would expire in 2028 if re‑elected .
- Committees:
- Audit Committee member (Chair: Jay Moyes) .
- Compensation Committee member (Chair: Mark Anderson) .
- Corporate Governance & Nominating Committee Chair .
- Committee activity: In 2024, committees did not meet separately; matters were addressed in Board meetings due to composition (pre‑April 2025 changes) .
- Board activity and attendance: The Board met 40 times in 2024; all directors attended >75% of Board and committee meetings of which they were members (board-level disclosure; Mitchell joined in April 2025) .
- Risk oversight: Board oversees strategic risk; Audit oversees financial risk/internal controls; Governance monitors governance effectiveness; Compensation monitors pay-related risk .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual Board retainer (cash) | $50,000 | Paid monthly ($4,166) |
| Audit Committee Chair retainer | $20,000 | Applies to Audit Chair only; Mitchell is a member, not Chair |
| Other Committee Chair retainer | $7,500 | Applies to non‑Audit committee chairs; Mitchell chairs Governance & Nominating |
| Meeting fees | Not disclosed | No per‑meeting fees disclosed |
| Expense reimbursement | Reasonable expenses reimbursed | With documentation |
Performance Compensation
| Equity Award Type | Typical Annual Grant | Vesting/Terms | Performance Metrics Tied to Director Pay |
|---|---|---|---|
| Stock options (non‑employee directors) | 10,000 shares | Strike price/expiration/vesting not disclosed | None disclosed for directors; policy does not specify performance conditions |
Pay-versus-performance disclosure in the proxy relates to NEOs, not directors; no director-specific performance metric framework is disclosed .
Other Directorships & Interlocks
| Company | Listing | Role | Interlock/Conflict Notes |
|---|---|---|---|
| Conavi Medical Corp. | TSX | Director; Chair HR & Governance | Public in Canada; not an SEC registrant; no SINT-related transactions disclosed |
| Life Seal Vascular Inc. | Private | Executive Chairman | No related-party transactions disclosed |
| FF20 Ventures; NLP Ventures | Private | General Partner | Venture roles; bylaws require disclosure/approval of any interested transactions by disinterested directors |
Expertise & Qualifications
- Deep medtech operating experience (CEO/President/COO roles at public/private medtech firms) .
- Governance expertise (chairs HR & Governance at Conavi; chairs SINT’s Corporate Governance & Nominating) .
- Commercial leadership (global sales roles at Align Technology and Cook Incorporated) .
- Education: B.S. (University of Utah), M.B.A. (Indiana Wesleyan University) .
Equity Ownership
| Holder | Instrument | Shares/Options | % of Outstanding | Notes |
|---|---|---|---|---|
| Robert Mitchell | Options to purchase common stock (currently exercisable) | 10,000 | <1% (*) | Outstanding shares: 2,755,587 as of July 1, 2025 |
(*) Indicates <1% of outstanding per proxy .
- Pledging/Hedging: No pledging or hedging disclosures identified for Mitchell; Section 16(a) compliance noted for 2023 at the company level .
Insider Trades
| Date Range Checked | Person | Findings | Source |
|---|---|---|---|
| 2024-01-01 to 2025-12-31 | Robert Mitchell | No Form 4 insider trades found for SINT | insider-trades skill run: fetch_insider_trades.py (no records returned) |
Governance Assessment
- Strengths:
- Independent director with substantial medtech governance and operating experience; chairs the Governance & Nominating Committee, a key lever for board effectiveness .
- Clear independence determination under Nasdaq rules; board majority independent .
- Director compensation structure is modest with equity via options, fostering alignment without evident guaranteed or discretionary components beyond standard retainers .
- No related‑party transactions involving Mitchell since Jan 1, 2023; bylaws require disclosure and disinterested approval for any interested transactions, mitigating conflict risk .
- Watch items / potential red flags:
- Multiple venture and private company affiliations (FF20 Ventures, NLP Ventures, RDM Enterprises, Life Seal Vascular) could create future conflicts if transactions arise; ongoing monitoring of related‑party disclosures is warranted .
- Committee activity in 2024 was handled at the Board level rather than separate meetings; post‑reconstitution effectiveness should be tracked (Mitchell joined in April 2025) .
- Equity ownership is limited (10,000 options; <1%), which may signal lower direct “skin‑in‑the‑game” versus higher ownership directors, although annual option grants provide some alignment .
Overall: Mitchell’s governance profile is additive for SINT given his chair role on Governance & Nominating and deep medtech background. Independence, absence of related‑party transactions, and standard director pay structures support investor confidence; monitor venture ties for potential conflicts and future director equity accumulation for alignment over time .